Sam Brusco, Associate Editor11.18.22
GE Healthcare’s Pharmaceutical Diagnostics business invested $80 million to boost manufacturing capacity by 30% at its Lindeses, Norway active pharmaceutical ingredients (API) site.
The investment will create about 100 new jobs and aims to address future demand for iodinated contrast media used in x-ray and CT procedures.
Iohexol and iodixanol API are used in over 100 million patient doses of GE iodinated contrast media annually, equivalent to three patient procedures every second. This new investment, coupled with the recent opening of a new production line at GE Healthcare’s Cork, Ireland, fill and finish facility, aims to enable production of 30 million more patient doses per year by 2025.
President and CEO of GE Healthcare Pharmaceutical Diagnostics, Kevin O’Neill told the press, “We expect global demand for iodinated contrast media to double in the next 10 years, driven by global prevalence of chronic disorders and significant growth in CT procedures. This investment in capacity expansion at our Lindesnes facility is another example of how we, as an industry leader, are addressing this growing demand to meet the needs of our customers and their patients across the globe.”
The 100-acre Lindesnes site in southern Norway, has been operating since 1974 and employs 450 people, who use multiple chemical pharmaceutical processes to convert iodine into finished API.
The investment will create about 100 new jobs and aims to address future demand for iodinated contrast media used in x-ray and CT procedures.
Iohexol and iodixanol API are used in over 100 million patient doses of GE iodinated contrast media annually, equivalent to three patient procedures every second. This new investment, coupled with the recent opening of a new production line at GE Healthcare’s Cork, Ireland, fill and finish facility, aims to enable production of 30 million more patient doses per year by 2025.
President and CEO of GE Healthcare Pharmaceutical Diagnostics, Kevin O’Neill told the press, “We expect global demand for iodinated contrast media to double in the next 10 years, driven by global prevalence of chronic disorders and significant growth in CT procedures. This investment in capacity expansion at our Lindesnes facility is another example of how we, as an industry leader, are addressing this growing demand to meet the needs of our customers and their patients across the globe.”
The 100-acre Lindesnes site in southern Norway, has been operating since 1974 and employs 450 people, who use multiple chemical pharmaceutical processes to convert iodine into finished API.